assessment

Europe is changing its assessment and giving limited approval to lecanemab, a controversial Alzheimer’s disease drug.

The European Medicines Agency (EMA) has re-evaluated the Alzheimer's drug lecanemab and decided to authorize the product. The decision comes…

6 hours ago

CLL is one of the most common types of blood cancer in Spain.

The VI practical course on the study and treatment of chronic lymphocytic leukemia (CLL), organized by the Spanish Group of…

1 month ago

WHO to evaluate first self-test for hepatitis C

The first self-tests to diagnose hepatitis C – as is done today with coronavirus tests and pharmacy tests – will…

4 months ago

WHO to evaluate first self-test for hepatitis C

The first self-tests to diagnose hepatitis C – as is done today with coronavirus tests and pharmacy tests – will…

4 months ago